Close Sidebar
Nordic Life Science
Now Reading
US FDA approves FARXIGA tablets for the treatment of adult patients with type 2 diabetes
Search for content, post, videos
Search for content, post, videos

US FDA approves FARXIGA tablets for the treatment of adult patients with type 2 diabetes

January 14, 2014
1382 Views
astra
AstraZeneca and Bristol-Myers Squibb Company announced the US Food and Drug Administration (FDA) approved FARXIGA™ [far-SEE-ga] (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. FARXIGA sh
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.

Malin Otmani

Related Posts

February 27, 2013

The two companies have entered an agreement regarding a preclinical program for a potential novel treatment of respiratory diseases (OX-CLI). Orexo grants to AstraZeneca rights to conduct further preclinical research and evaluation of compounds in Orexo’s OX-CLI program. AstraZeneca also has an opAlready a subscriber Login You have read all…

Sobi Research
January 23, 2018

Swedish Orphan Biovitrum announces that the FDA has issued a Study may proceed letter for the first study in humans, thereby accepting the investigational new drug (IND) application for the drug candidate SOBI003. In addition, SOBI003 was granted Fast Track status by the FDA. SOBI003 is a cheAlready a subscriber Login You have read…

February 25, 2015

Bavarian Nordic plans to present updated overall survival data from an NCI sponsored combination study of its active prostate cancer immunotherapy candidate PROSTVAC and ipilimumab, an immune checkpoint inhibitor, at the Genitourinary Cancers Symposium in Orlando, FL on Feb. 26. Approximately Already a subscriber Login You have read all your free articles, to…